Healionics Raises $4.7M Equity Round To Support Commercialization Of Stargraft Vascular Graft
05/13/21, 1:31 PM
Location
seattle
Money raised
$4.7 million
Round Type
seed
Healionics Corporation, a private medical device company, announced today the completion of a $4.7M equity financing round led by Keiretsu Capital. The company also announced the conversion to equity of $5.2M in previously outstanding notes and interest.
Company Info
Location
seattle, washington, united states
Additional Info
Healionics is a clinical-stage company addressing the critical need for safer, more reliable means to access the bloodstream for dialysis in patients with kidney failure. Its STARgraft vascular graft is designed to resist the problems of infection and occlusion suffered by current devices. The company also has an exciting product pipeline based on its platform STARĀ® biomaterial, which has a unique ability to resist both infection and scarring, two problems that affect all implanted devices. www.healionics.com
SOURCE Healionics Corporation